In a significant development for vision care, Entod Pharmaceuticals has introduced the first eye drop in India designed to address presbyopia. This new treatment, named PresVu, received marketing authorization from the Drugs Controller General of India (DCGI) last month and was officially launched on Tuesday. Presbyopia, a common vision condition that affects individuals over 40, makes it difficult to focus on close objects. PresVu contains 1.25 percent pilocarpine hydrochloride, a compound derived from plants that has been used for various eye treatments for years.
Affordable And Accessible
Developed by Mumbai-based Entod Pharmaceuticals, PresVu is priced at Rs 345 per vial, which is expected to last for about a month. The eye drops are anticipated to be available in pharmacies across India starting October. Nikhil Masurkar, CEO of Entod Pharmaceuticals, highlighted that the launch follows extensive research that began in 2019. It is estimated that nearly 45 percent of Indians over the age of 40 suffer from presbyopia, making this new treatment highly relevant.
Similar Treatment In The US
A similar eye drop formulation was introduced in the US in 2022 under the brand name Vuity. Vuity is the only FDA-approved eye drop for treating age-related blurry vision. PresVu follows in its footsteps, offering an alternative to traditional reading glasses and contact lenses.
How PresVu Works
According to phase 3 clinical trials involving 250 patients, PresVu is most effective for individuals aged 40 to 55 with mild-to-intermediate presbyopia. The eye drop must be used under the guidance of an ophthalmologist, with one drop recommended for each eye daily. The effects last about six hours, with the possibility of a second dose extending the benefits for an additional three hours. Initial effects are visible within 15 minutes, though full benefits are achieved after 15 days of use.
Expert Opinions And Benefits
Dr. Dhananjay Bakhle, a senior pharmacologist and advisor to Entod Pharmaceuticals, noted that PresVu offers a non-invasive option for improving near vision without the need for reading glasses. Dr. Aditya Sethi emphasized that the eye drop provides a quick solution for presbyopia, enhancing near vision within just 15 minutes. The formulation not only improves vision but also lubricates the eyes, providing additional comfort.
Looking Ahead
With its approval from the DCGI and positive feedback from clinical trials, PresVu represents a promising advancement in eye care. As it becomes available in the coming months, it could transform how millions of people manage age-related vision changes, offering a convenient and effective alternative to traditional corrective measures.